Page last updated: 2024-10-24

regulation of skeletal muscle satellite cell proliferation

Definition

Target type: biologicalprocess

Any process that modulates the frequency, rate or extent of skeletal muscle satellite cell proliferation. [GOC:ef, GOC:mtg_muscle, PMID:16607119]

Skeletal muscle satellite cells (SCs) are quiescent stem cells residing beneath the basal lamina of muscle fibers. They play a critical role in muscle regeneration by proliferating and differentiating into myoblasts, which fuse to form new muscle fibers. The regulation of SC proliferation is a tightly controlled process, involving a complex interplay of intrinsic and extrinsic factors.

**Intrinsic Factors:**

* **Transcription factors:** Myogenic regulatory factors (MRFs) such as Myf5, MyoD, and Myogenin are key regulators of SC proliferation and differentiation. Myf5 is required for SC specification, while MyoD promotes SC proliferation. Myogenin is essential for the terminal differentiation of myoblasts into myotubes.
* **Cell cycle regulators:** Cyclin-dependent kinases (CDKs) and their regulatory subunits, cyclins, control cell cycle progression. The expression of specific CDKs and cyclins is regulated during SC activation and proliferation.
* **MicroRNAs:** These small non-coding RNAs regulate gene expression at the post-transcriptional level. Several microRNAs have been implicated in the regulation of SC proliferation, including miR-206 and miR-133.

**Extrinsic Factors:**

* **Growth factors:** Several growth factors, including insulin-like growth factor 1 (IGF-1), fibroblast growth factor 2 (FGF2), and hepatocyte growth factor (HGF), promote SC proliferation. These factors activate signaling pathways that lead to the expression of genes involved in cell cycle progression.
* **Cytokines:** Inflammatory cytokines, such as TNF-α and IL-6, can both promote and inhibit SC proliferation depending on the context.
* **Extracellular matrix (ECM):** The ECM provides structural support and signaling cues for SCs. Laminin and collagen are major ECM components that influence SC adhesion, proliferation, and differentiation.
* **Mechanical stimuli:** Muscle stretching and contraction can activate SCs and promote their proliferation. This is mediated by mechanotransduction pathways involving integrins and focal adhesion kinases.

**Regulation of SC Proliferation During Muscle Regeneration:**

Upon muscle injury, quiescent SCs are activated and enter the cell cycle. This activation is triggered by signals released from damaged muscle fibers and inflammatory cells. SC proliferation is tightly controlled to ensure proper muscle regeneration. As SCs proliferate, they migrate to the site of injury and differentiate into myoblasts. Eventually, the proliferative pool of SCs is depleted, and differentiation becomes dominant, leading to the formation of new muscle fibers.

**Factors Influencing SC Proliferation:**

* **Age:** SC function declines with age, resulting in reduced regenerative capacity.
* **Disease:** Various muscle diseases, such as muscular dystrophy, can impair SC function and limit muscle regeneration.
* **Nutritional status:** Nutrients, such as amino acids and protein, are essential for SC proliferation and differentiation.

**Future Directions:**

* Understanding the complex interplay of intrinsic and extrinsic factors that regulate SC proliferation is crucial for developing therapies for muscle regeneration.
* Targeting specific pathways involved in SC activation, proliferation, and differentiation could lead to the development of novel regenerative therapies for muscle injuries and diseases.'
"

Proteins (1)

ProteinDefinitionTaxonomy
Peroxisome proliferator-activated receptor deltaA peroxisome proliferator-activated receptor delta that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q03181]Homo sapiens (human)

Compounds (45)

CompoundDefinitionClassesRoles
gw 2433GW 2433: binds peroxisome proliferator-activated receptor alpha (PPARalpha); structure in first source
clofibric acidclofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.

Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
aromatic ether;
monocarboxylic acid;
monochlorobenzenes
anticholesteremic drug;
antilipemic drug;
antineoplastic agent;
herbicide;
marine xenobiotic metabolite;
PPARalpha agonist
pirinixic acidpirinixic acid: structurearyl sulfide;
organochlorine compound;
pyrimidines
methyleugenolmethyleugenol: structurephenylpropanoid
myristic acidMyristic Acid: A saturated 14-carbon fatty acid occurring in most animal and vegetable fats, particularly butterfat and coconut, palm, and nutmeg oils. It is used to synthesize flavor and as an ingredient in soaps and cosmetics. (From Dorland, 28th ed)

tetradecanoate : A long-chain fatty acid anion that is the conjugate base of myristic acid; major species at pH 7.3.

tetradecanoic acid : A straight-chain, fourteen-carbon, long-chain saturated fatty acid mostly found in milk fat.
long-chain fatty acid;
straight-chain saturated fatty acid
algal metabolite;
Daphnia magna metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite
bezafibratearomatic ether;
monocarboxylic acid;
monocarboxylic acid amide;
monochlorobenzenes
antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic
fenofibric acidfenofibric acid : A monocarboxylic acid that is 2-methylpropanoic acid substituted by a 4-(4-chlorobenzoyl)phenoxy group at position 2. It is a metabolite of the drug fenofibrate.

fenofibric acid: RN given refers to parent cpd without isomeric designation; structure
aromatic ketone;
chlorobenzophenone;
monocarboxylic acid
drug metabolite;
marine xenobiotic metabolite
telmisartantelmisartan : A member of the class of benzimidazoles used widely in the treatment of hypertension.

Telmisartan: A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION.
benzimidazoles;
biphenyls;
carboxybiphenyl
angiotensin receptor antagonist;
antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
environmental contaminant;
xenobiotic
rosiglitazoneaminopyridine;
thiazolidinediones
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
insulin-sensitizing drug
2-bromopalmitate2-bromohexadecanoic acid : A bromo fatty acid that is hexadecanoic (palmitic) acid carrying a single bromo substituent at position 2.

2-bromopalmitate: inhibitor of fatty acid oxidation; RN given refers to parent cpd
2-bromocarboxylic acid;
bromo fatty acid;
long-chain fatty acid;
straight-chain fatty acid
fatty acid oxidation inhibitor
mk 7675-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide: an antihyperlipidemic agent that also functions as an insulin sensitizer, PPARalpha agonist, and PPARgamma agonist; structure in first source
anacardic acidanacardic acid : A hydroxybenzoic acid that is salicylic acid substituted by a pentadecyl group at position 6. It is a major component of cashew nut shell liquid and exhibits an extensive range of bioactivities.

anacardic acid: isolated from Anacardium occidentale; monophenol monooxygenase inhibitor
hydroxy monocarboxylic acid;
hydroxybenzoic acid
anti-inflammatory agent;
antibacterial agent;
anticoronaviral agent;
apoptosis inducer;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
neuroprotective agent;
plant metabolite
farglitazarfarglitazar: a non-thiazolidinedione insulin sensitiser and PPARgamma agonist
syringaresinol(+)-syringaresinol : The (7alpha,7'alpha,8alpha,8'alpha)-stereoisomer of syringaresinol.syringaresinolantineoplastic agent
oleic acidoleic acid : An octadec-9-enoic acid in which the double bond at C-9 has Z (cis) stereochemistry.

Oleic Acid: An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (Stedman, 26th ed)
octadec-9-enoic acidantioxidant;
Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
Escherichia coli metabolite;
mouse metabolite;
plant metabolite;
solvent
epipinoresinolepipinoresinol : An enantiomer of pinoresinol having (+)-(1R,3aR,4S,6aR)-configuration.pinoresinolmarine metabolite;
plant metabolite
t 0070907T 0070907: a PPARgamma antagonist; structure in first sourcecarbonyl compound;
organohalogen compound
gsk 3787
2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide: structure given in first source
gw 7647GW 7647 : A monocarboxylic acid that is 2-(phenylsulfanyl)isobutyric acid in which the phenyl group is substituted at the para- position by a 3-aza-7-cyclohexylhept-1-yl group in which the nitrogen is acylated by a (cyclohexylamino)carbonyl group.

GW 7647: a PPAR-alpha agonist; structure in first source
aryl sulfide;
monocarboxylic acid;
ureas
PPARalpha agonist
psi-baptigeninpseudobaptigenin : A member of the class of 7-hydroxyisoflavones that is 7-hydroxyisoflavone and in which the phenyl group at position 3 is replaced by a 1,3-benzodioxol-5-yl group.7-hydroxyisoflavones;
benzodioxoles
antiprotozoal drug;
plant metabolite
n-oleoylethanolamineN-oleoylethanolamine: ceramidase inhibitor

oleoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of oleic acid. The monounsaturated analogue of the endocannabinoid anandamide.
endocannabinoid;
N-(long-chain-acyl)ethanolamine;
N-acylethanolamine 18:1
EC 3.5.1.23 (ceramidase) inhibitor;
geroprotector;
PPARalpha agonist
pregna-4,17-diene-3,16-dionepregna-4,17-diene-3,16-dione: steroid from guggulu extract; RN & N1 from C1 Form index; RN given refers to cpd without isomeric designation; structure in first source; antagonist of farnesoid X receptor3-hydroxy steroidandrogen
gw 1929GW 1929: activates peroxisome proliferator-activated receptor-gamma; structure in first sourcebenzophenones
l-1650414-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid: a PPAR-delta agonist has regulatory effects on a variety of adipokines, and these effects might explain some of their metabolic function.aromatic ketone
gw 501516GW 501516 : An aromatic ether that is phenoxyacetic acid in which the phenyl group is substituted at position 2 by a methyl group and at position 4 by a (1,3-thiazol-5-ylmethyl)sulfanediyl group, and in which the 1,3-thiazolyl group is substituted at positions 2 and 4 by p-trifluoromethylphenyl and methyl groups, respectively.

GW 501516: a selective PPARdelta agonist; structure in first source
1,3-thiazoles;
aromatic ether;
aryl sulfide;
monocarboxylic acid;
organofluorine compound
carcinogenic agent;
PPARbeta/delta agonist
tzd 18
gft505
gw 9578GW 9578: a peroxisome proliferator-activated receptor alpha agonist; structure in first source
gw 7845GW 7845: ligand of the peroxisome proliferator-activated receptor-gamma; structure in first source
naveglitazarnaveglitazar: LY-519818 is the (alpha-S)-isomer; an antidiabetic agent; structure in first sourcearomatic ether
l 796449L 796449: a peroxisomal proliferator-activated receptor-gamma agonist; structure in first source
gw0742GW 610742: structure in first sourcemonocarboxylic acid
3-chloro-4-(3-(7-propyl-3-trifluoromethyl-6-benzisoxazolyl)propylthio)phenylacetic acid
ns-220
gw 5907352-methyl-2-(4-(((4-methyl-2-(4-trifluoromethylphenyl)-thiazol-5-ylcarbonyl)amino)methyl)phenoxy)propionic acid: an HDLc raising agent; structure in first source
aleglitazaraleglitazar: a dual peroxisome PPAR-alpha and PPAR-gamma agonist for type 2 diabetes
mbx-8025seladelpar: PPAR-delta agonist
gw9508GW9508: structure in first sourcearomatic amine
lj 529
bms 687453
amorfrutin aamorfrutin A: an antidiabetic agent that inhibits NF-kappaB activation; structure in first sourcestilbenoid
amorfrutin bamorfrutin B: structure in first source
gsk0660GSK0660: PPAR antagonist; structure in first sourcesulfonamide
ly 518674LY 518674: a peroxisome proliferator-activated receptor alpha agonist; structure in first source